Laboratorios Recalcine Sa.. Pharmaceutical Import Profile — Chile (DGFT 2022–2026)

Name: Laboratorios Recalcine Sa.. Pharmaceutical Import Records from India — 2 Products, $5.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Laboratorios Recalcine Sa.. — Pharmaceutical Importer Profile (2026) | 2 Products, $5.3M Trade | TransData Nexus

Laboratorios Recalcine Sa..

Pharmaceutical Importer · Chile · Respiratory Focus · $5.3M Total Trade · DGFT Verified

Laboratorios Recalcine Sa.. is a pharmaceutical importer based in Chile with a total trade value of $5.3M across 2 products in 1 therapeutic categories. Based on 167 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Laboratorios Recalcine Sa.. sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Laboratorios Recalcine Sa.. — Import Portfolio & Supplier Network

Laboratorios Recalcine Sa.. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Laboratorios Recalcine Sa..?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$3.9M	246	100.0%

Laboratorios Recalcine Sa.. sources from 1 verified Indian supplier across 81 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Laboratorios Recalcine Sa.. Import?

Formulation	Value	Ships
Aerovial 200 MCG inh cfc free	$1.1M	32
Aurituss inhaler (25/250) (salmeterol xinafoate 25mcg + fluticasone propionate 250mcg (1x120 md)	$483.4K	16
Aurituss inhaler (25/250) (salmeterol xinafoate 25mcg + fluticasone propionate 250mcg )	$210.0K	7
Aerovial 200mcg inh cfc free recalcine-cl (budesonide inhaler) MCG) (1x200 md)	$209.8K	8
Aurituss inhaler (25/250) (salmeterol xinafoate 25 MCG+fluticasone propionate 250mcg) (1x120 md)	$208.6K	7
Aurituss inhaler (25/250) (salmeterol xinafoate 25 MCG+fluticasone propionate 250 MCG)	$180.8K	6
Aerovial 200mcg inh cfc free recalcine-cl (budesonide inhaler) (1x200 md)	$156.1K	6
Aurituss inhaler (25/250) (salmeterol xinafoate 25 MCG+fluticasone propionate 250mcg )	$152.0K	5
Aurituss inhaler (25/250) (salmeterol xinafoate 25 MCG+fluticasone propionate 250mcg ) 1 x 120	$149.6K	5
Aurituss inhaler (25/250)(salmeterol xinafoate 25mcg+fluticasone propionate 250 MCG) (1x120 md)	$149.1K	5
Salmeterol aerosol para inhalacion25 MCG/dosis (cfc free)(salmeterol xinafoate 25 MCG) (1x120 md)	$104.1K	3
Flusona lf 125mcg inhaler ( fluticasone propionate inhaler 125mcg) (1x120 md)	$103.8K	5
Aurituss inhaler (25/250) (salmeterol	$100.0K	2
Bropil lf 100 MCG cfc free inhaler	$95.8K	4
Aurituss inhaler (25/250) (salmeterol xinafoate 25mcg + fluticasone propionate 250mcg) (1x200 md)	$89.9K	3

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Salmeterol	Respiratory	$3.4M	103	2.8%	8
2	Fluticasone	Respiratory	$1.9M	64	0.9%	16

Laboratorios Recalcine Sa.. imports 2 pharmaceutical products across 1 categories into Chile totaling $5.3M.

Laboratorios Recalcine Sa.. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Laboratorios Recalcine S.A., established in 2004, is a prominent Chilean pharmaceutical company specializing in the development, production, and sale of pharmaceutical drugs. Headquartered in Santiago, Chile, the company operates across 15 Latin American countries, including Argentina, Bolivia, Colombia, Costa Rica, Ecuador, Paraguay, Peru, and Venezuela, as well as in Vietnam. In 2010, Laboratorios Recalcine S.A. rebranded to CFR Pharmaceutical S.A., and in 2014, it was acquired by Abbott Laboratories, significantly expanding Abbott's presence in the Latin American market.

2Distribution Network

Laboratorios Recalcine S.A. maintains a robust distribution network with multiple warehouse locations throughout Chile, including facilities in Santiago, Viña del Mar, Rancagua, Temuco, and Concepción. This extensive network enables efficient logistics capabilities, ensuring timely delivery of pharmaceutical products across the country. The company's geographic coverage extends beyond Chile, serving various Latin American nations and Vietnam, thereby enhancing its regional and international reach.

3Industry Role

In Chile's pharmaceutical supply chain, Laboratorios Recalcine S.A. functions primarily as a wholesaler and distributor. The company imports finished pharmaceutical formulations from various international suppliers, including India, and distributes these products to pharmacies, hospitals, and other healthcare providers across the country. This role is crucial in ensuring the availability of a diverse range of pharmaceutical products to meet the healthcare needs of the Chilean population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Laboratorios Recalcine Sa..

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Laboratorios Recalcine S.A. exhibits a high degree of supplier concentration, with a total import value of $5.3 million USD from India, comprising 167 shipments of 81 unique formulations. Notably, all these imports are sourced from a single supplier, CIPLA LIMITED, indicating a strategic choice to maintain a consistent and reliable supply chain. This single-source dependency may pose risks related to supply chain disruptions; however, the company's established relationship with CIPLA LIMITED suggests a stable and dependable partnership.

2Supply Chain Resilience

The resilience of Laboratorios Recalcine S.A.'s Indian supply chain is bolstered by its diversified portfolio of 81 unique formulations. While the company relies on a single supplier, CIPLA LIMITED, the extensive range of formulations mitigates the impact of potential supply chain disruptions. The established relationship with CIPLA LIMITED, a reputable supplier, further enhances the stability and reliability of the supply chain.

3Strategic Implications

Importing Pharmaceuticals into Chile — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Chile

1Regulatory Authority & Framework

In Chile, the primary regulatory authority overseeing pharmaceutical imports is the Public Health Institute of Chile (Instituto de Salud Pública de Chile, ISP). The ISP is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Chilean market. Key legislation governing pharmaceutical imports includes the Health Code (Código Sanitario) and the Pharmaceutical Regulations (Reglamento Sanitario de los Alimentos), which outline the requirements for marketing authorization, labeling, and distribution of pharmaceutical products.

2Import Licensing & GMP

Import licensing requirements in Chile stipulate that pharmaceutical products must obtain marketing authorization from the ISP before entering the market. This process involves submitting comprehensive documentation, including evidence of Good Manufacturing Practice (GMP) compliance. Chile recognizes GMP certifications from reputable international bodies, such as the European Medicines Agency (EMA) and the World Health Organization (WHO), facilitating the entry of foreign pharmaceutical products into the Chilean market.

3Quality & Labeling

Laboratorios Recalcine Sa.. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Laboratorios Recalcine S.A. focuses on importing pharmaceutical products in the respiratory therapeutic category, with significant investments in formulations such as Salmeterol and Fluticasone. This strategic focus aligns with the high demand for respiratory medications in Chile, driven by factors such as air quality concerns and the prevalence of respiratory conditions. The company's product strategy ensures it meets the specific healthcare needs of the Chilean population.

2Sourcing Profile

Laboratorios Recalcine S.A. employs a sourcing strategy that emphasizes the importation of generic drug formulations, particularly in the respiratory category. The company's preference for sourcing from India is driven by the availability of high-quality, cost-effective formulations that meet international standards. This approach allows Laboratorios Recalcine S.A. to offer a diverse range of pharmaceutical products to the Chilean market.

3Market Positioning

Based on its product mix, Laboratorios Recalcine S.A. serves multiple segments of the Chilean pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on respiratory medications positions it as a key supplier in the treatment of respiratory conditions, catering to a broad spectrum of healthcare providers and patients.

Seller's Guide — How to Become a Supplier to Laboratorios Recalcine Sa..

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Laboratorios Recalcine S.A., given the company's established sourcing pattern and the high demand for respiratory medications in Chile. Potential gaps in Laboratorios Recalcine S.A.'s current sourcing include the need for additional suppliers to diversify the supply chain and mitigate risks associated with single-source dependency. Indian exporters can leverage this opportunity by offering high-quality formulations that meet the specific needs of the Chilean market.

2Requirements & Qualifications

Indian exporters seeking to supply Laboratorios Recalcine S.A. and the Chilean market must ensure compliance with GMP standards recognized by international bodies such as the EMA and WHO. Additionally, they must adhere to Chilean regulations regarding import licensing, labeling, and quality control. Obtaining marketing authorization from the ISP is a critical step in entering the Chilean market.

3How to Approach

Frequently Asked Questions — Laboratorios Recalcine Sa..

What products does Laboratorios Recalcine Sa.. import from India?

Laboratorios Recalcine Sa.. imports 2 pharmaceutical products across 1 categories. Top imports: Salmeterol ($3.4M), Fluticasone ($1.9M).

Who supplies pharmaceuticals to Laboratorios Recalcine Sa.. from India?

Laboratorios Recalcine Sa.. sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $3.9M).

What is Laboratorios Recalcine Sa..'s total pharmaceutical import value?

Laboratorios Recalcine Sa..'s total pharmaceutical import value from India is $5.3M, based on 167 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Laboratorios Recalcine Sa.. focus on?

Laboratorios Recalcine Sa.. imports across 1 categories. The largest: Respiratory (100.0%).

Get Full Laboratorios Recalcine Sa.. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.